Xenon Pharmaceuticals Inc.

NasdaqGM:XENE Stock Report

Market Cap: US$2.7b

Xenon Pharmaceuticals Valuation

Is XENE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XENE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$140.86
Fair Value
75.1% undervalued intrinsic discount
17
Number of Analysts

Below Fair Value: XENE ($35.02) is trading below our estimate of fair value ($140.86)

Significantly Below Fair Value: XENE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XENE?

Key metric: As XENE is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for XENE. This is calculated by dividing XENE's market cap by their current book value.
What is XENE's PB Ratio?
PB Ratio3.6x
BookUS$754.90m
Market CapUS$2.68b

Price to Book Ratio vs Peers

How does XENE's PB Ratio compare to its peers?

The above table shows the PB ratio for XENE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.4x
SRRK Scholar Rock Holding
7.9x62.5%US$2.9b
CGON CG Oncology
2.5x51.5%US$1.8b
SYRE Spyre Therapeutics
2.6x-17.4%US$851.0m
VIR Vir Biotechnology
0.7x16.3%US$702.9m
XENE Xenon Pharmaceuticals
3.6x24.6%US$2.7b

Price-To-Book vs Peers: XENE is expensive based on its Price-To-Book Ratio (3.6x) compared to the peer average (3.4x).

Price to Book Ratio vs Industry

How does XENE's PB Ratio compare vs other companies in the US Biotechs Industry?

84 CompaniesPrice / BookEstimated GrowthMarket Cap
FDMT 4D Molecular Therapeutics
0.3x-5.8%US$142.68m
NKTX Nkarta
0.3x-2.3%US$136.95m
FATE Fate Therapeutics
0.4x-5.5%US$119.19m
LYEL Lyell Immunopharma
0.3x5.5%US$118.14m
XENE 3.6xIndustry Avg. 1.4xNo. of Companies87PB01.63.24.86.48+
84 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: XENE is expensive based on its Price-To-Book Ratio (3.6x) compared to the US Biotechs industry average (1.4x).

Price to Book Ratio vs Fair Ratio

What is XENE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XENE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate XENE's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XENE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$35.02
US$57.18
+63.3%
10.7%US$65.00US$42.00n/a17
May ’26US$38.09
US$57.31
+50.5%
11.0%US$65.00US$42.00n/a16
Apr ’26US$30.64
US$57.81
+88.7%
10.7%US$65.00US$42.00n/a16
Mar ’26US$37.02
US$57.81
+56.2%
10.7%US$65.00US$42.00n/a16
Feb ’26US$39.98
US$57.80
+44.6%
10.2%US$65.00US$43.00n/a15
Jan ’26US$39.20
US$57.67
+47.1%
8.9%US$65.00US$46.00n/a15
Dec ’25US$42.63
US$57.18
+34.1%
9.2%US$65.00US$46.00n/a16
Nov ’25US$41.69
US$57.27
+37.4%
8.9%US$65.00US$49.00n/a15
Oct ’25US$40.38
US$57.79
+43.1%
8.5%US$65.00US$49.00n/a14
Sep ’25US$40.34
US$58.15
+44.2%
8.4%US$65.00US$49.00n/a13
Aug ’25US$43.73
US$58.79
+34.4%
7.9%US$65.00US$50.00n/a14
Jul ’25US$37.69
US$58.79
+56.0%
7.9%US$65.00US$50.00n/a14
Jun ’25US$38.07
US$58.63
+54.0%
7.7%US$65.00US$50.00n/a15
May ’25US$42.49
US$57.44
+35.2%
9.3%US$65.00US$45.00US$38.0917
Apr ’25US$42.14
US$57.44
+36.3%
9.3%US$65.00US$45.00US$30.6417
Mar ’25US$46.84
US$57.38
+22.5%
9.3%US$65.00US$45.00US$37.0217
Feb ’25US$46.43
US$54.41
+17.2%
11.3%US$63.00US$45.00US$39.9816
Jan ’25US$46.06
US$53.63
+16.4%
11.2%US$63.00US$45.00US$39.2015
Dec ’24US$36.80
US$51.96
+41.2%
9.2%US$60.00US$45.00US$42.6314
Nov ’24US$31.22
US$51.86
+66.1%
8.3%US$60.00US$46.00US$41.6914
Oct ’24US$34.16
US$52.27
+53.0%
8.5%US$60.00US$46.00US$40.3815
Sep ’24US$39.73
US$52.27
+31.6%
8.5%US$60.00US$46.00US$40.3415
Aug ’24US$37.38
US$52.20
+39.6%
8.1%US$60.00US$46.00US$43.7315
Jul ’24US$38.50
US$52.20
+35.6%
8.1%US$60.00US$46.00US$37.6915
Jun ’24US$38.65
US$52.20
+35.1%
8.1%US$60.00US$46.00US$38.0715
May ’24US$39.98
US$51.33
+28.4%
9.7%US$60.00US$44.00US$42.4915
AnalystConsensusTarget
Consensus Narrative from 17 Analysts
US$57.18
Fair Value
38.8% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 13:48
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xenon Pharmaceuticals Inc. is covered by 24 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason Matthew GerberryBofA Global Research
John NewmanCanaccord Genuity